← Back to Screener
aTyr Pharma, Inc. Common Stock (ATYR)
Price$0.55
Growth ScoreF
Momentum ScoreD
Favorite Metrics
Price vs S&P 500 (26W)-32.60%
Price vs S&P 500 (4W)-39.92%
VGM Score19.37
Market Capitalization$53.19M
All Metrics
Book Value / Share (Quarterly)$0.59
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-73.65%
Cash Flow / Share (Quarterly)$-0.60
Price vs S&P 500 (YTD)-41.65%
Net Profit Margin (TTM)-13549.47%
EPS (TTM)$-0.80
10-Day Avg Trading Volume4.13M
EPS Excl Extra (TTM)$-0.80
Revenue Growth (5Y)-55.14%
EPS (Annual)$-0.80
ROI (Annual)-108.41%
Net Profit Margin (5Y Avg)-16223.90%
Cash / Share (Quarterly)$0.68
ROA (Last FY)-79.69%
Revenue Growth TTM (YoY)-19.15%
EBITD / Share (TTM)$-0.83
ROE (5Y Avg)-70.24%
Operating Margin (TTM)-14076.32%
Cash Flow / Share (Annual)$-0.63
P/B Ratio0.92x
P/B Ratio (Quarterly)1.32x
Net Income / Employee (Annual)$-1,323,500
Net Interest Coverage (TTM)-123.28x
ROA (TTM)-74.41%
EPS Incl Extra (Annual)$-0.80
Current Ratio (Annual)5.30x
Quick Ratio (Quarterly)5.73x
3-Month Avg Trading Volume2.20M
52-Week Price Return-87.25%
Revenue / Employee (TTM)$3,400
P/S Ratio (Annual)279.96x
Asset Turnover (Annual)0.00x
52-Week High$7.29
Operating Margin (5Y Avg)-17182.53%
EPS Excl Extra (Annual)$-0.80
CapEx CAGR (5Y)-17.54%
26-Week Price Return-16.67%
Quick Ratio (Annual)5.25x
13-Week Price Return-45.20%
Total Debt / Equity (Annual)0.01x
Current Ratio (Quarterly)5.78x
Enterprise Value$43.93M
Revenue / Share Growth (5Y)-71.90%
Asset Turnover (TTM)0.00x
Revenue / Employee (Annual)$3,400
Pretax Margin (Annual)-39012.11%
Cash / Share (Annual)$0.80
3-Month Return Std Dev157.98%
Net Income / Employee (TTM)$-1,323,500
ROE (Last FY)-109.84%
Net Interest Coverage (Annual)-212.81x
EPS Basic Excl Extra (Annual)$-0.80
Total Debt / Equity (Quarterly)0.01x
EPS Incl Extra (TTM)$-0.80
ROI (TTM)-98.17%
P/S Ratio (TTM)279.96x
Pretax Margin (5Y Avg)-16224.82%
Revenue / Share (Annual)$0.00
Price vs S&P 500 (52W)-115.46%
Year-to-Date Return-30.72%
5-Day Price Return10.71%
EPS Normalized (Annual)$-0.80
ROA (5Y Avg)-52.83%
Net Profit Margin (Annual)-39009.47%
Month-to-Date Return-32.78%
EBITD / Share (Annual)$-0.83
Operating Margin (Annual)-40856.32%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-69.13%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-0.80
P/B Ratio (Annual)1.14x
Pretax Margin (TTM)-13550.53%
Book Value / Share (Annual)$0.69
Price vs S&P 500 (13W)-54.95%
Beta0.56x
Revenue / Share (TTM)$0.00
ROE (TTM)-99.62%
52-Week Low$0.40
gGradeF
mGradeD
vgmGradeF
Show chart for
Earnings Surprise History
Q1 26-0.11est. -0.14
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
3.69
3.71
3.69
3.69
Industry Peers — Biological Products(178)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
ATYRaTyr Pharma, Inc. Common Stock | — | F | D | $0.55 |
| AMGNAmgen Inc | C | C | C | $329.13 |
| GILDGilead Sciences Inc | C | B | C | $131.10 |
| ARGXargenx SE American Depositary Shares | D | A | C | $836.09 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $163.68 |
| BIIBBiogen Inc. Common Stock | B | D | B | $192.23 |
| BNTXBioNTech SE American Depositary Share | C | C | C | $91.70 |
| MRNAModerna, Inc. Common Stock | C | B | B | $46.06 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $161.00 |
| EXELExelixis Inc | C | B | B | $50.28 |
| KRYSKrystal Biotech, Inc. Common Stock | D | B | B | $298.10 |
About
aTyr Pharma develops biotherapeutics using a proprietary tRNA synthetase platform. Its lead candidate, efzofitimod, is a clinical-stage treatment that targets NRP2 to address chronic inflammation and fibrosis, particularly in lung disease. The approach exploits a novel mechanism based on the extracellular signaling pathways of tRNA synthetases.